It confers a more aggressive phenotype and, historically, has been associated with poor patient prognosis.1 HER2‐targeted therapies, such as the anti‐HER2 antibody (Ab) trastuzumab, have been shown to improve outcomes in patients with HER2‐positive, metastatic disease. Here, ERBB2 is linked to metastatic neoplasm.